First results of a prospective bendamustine/rituximab trial in patients with MCL

Bookmark and Share
Published: 6 Jun 2016
Views: 2311
Dr Mathias Rummel - University of Giessen, Giessen, Germany

Dr Rummel talks to ecancertv at ASCO 2016, about the first results of a prospective, randomised, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

The study compares two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab in patients with mantle cell lymphoma.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.